Entries by Max
European Commission Approves Darolutamide Plus ADT for Metastatic Hormone-Sensitive Prostate Cancer
The European Commission has granted marketing authorization to darolutamide (Nubeqa) combined with androgen deprivation therapy (ADT) for treating metastatic hormone-sensitive prostate cancer (mHSPC). This approval, following a positive opinion from the European Medicines Agency in June 2025, allows darolutamide plus ADT to be used with or without docetaxel, offering clinicians greater flexibility in tailoring treatment. […]
Newsletter 29/2025
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! Apparently, research never fully takes a break. While most of the major news will come in the fall, we still have some interesting results this week. Stay strong and fight on! As usual, we also have a podcast if […]